VERACYTE, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount
VERACYTE, INC. (VCYT) had Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount of $0 as of 2020-09-30, per its 10-Q filed 2020-11-02.
Discontinued › Notes › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount · last filed 2020-11-02
- 2020-09-30: Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount $0.00.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount |
|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |